Is the DLQI appropriate for medical decision-making in psoriasis patients?
- 1 January 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Archiv für dermatologische Forschung
- Vol. 310 (1), 47-55
- https://doi.org/10.1007/s00403-017-1794-4
Abstract
Dermatology Life Quality Index (DLQI) is the most commonly applied measure of health-related quality of life (HRQoL) in psoriasis patients. It is among defining criteria of moderate-to-severe psoriasis and present in treatment guidelines. Our objective was to estimate preference-based HRQoL values (i.e., utilities) for hypothetical health states described by the 10 items of the DLQI in psoriasis patients. Moreover, we compare results to findings of a similar study previously conducted among the general public. A cross-sectional survey was carried out among 238 psoriasis patients. Seven hypothetical DLQI-defined health states with total scores of 6, 11, and 16 (3-3 and 1 states, respectively) were evaluated by time trade-off method. The difference in DLQI scores between hypothetical health states was set at 5 points, as it exceeds the minimal clinically important difference (MCID). Utility scores were found to be homogenous across the seven hypothetical health states (range of means for the 6-point states 0.85-0.91, range of means for the 11-point states 0.83-0.85, and mean of 0.84 for the 16-point state). Overall, mean utilities assessed by psoriasis patients were higher for all seven states compared with the general public (mean difference 0.16-0.28; p < 0.001). In 11 out of the 15 comparisons between health states with DLQI scores differing larger than the MCID, there was no statistically significant difference in utility. Thus, in clinical settings, patients with DLQI scores differing more than the MCID may have identical HRQoL. Improving the definition of moderate-to-severe disease and reconsideration of the DLQI in clinical assessment of psoriasis patients are suggested.Keywords
This publication has 55 references indexed in Scilit:
- Time trade-off: one methodology, different methodsThe European Journal of Health Economics, 2013
- Measuring melasma patients' quality of life using willingness to pay and time trade-off methods in thai populationBMC Dermatology, 2011
- Definition of treatment goals for moderate to severe psoriasis: a European consensusArchiv für dermatologische Forschung, 2010
- Valuation of scleroderma and psoriatic arthritis health states by the general publicHealth and Quality of Life Outcomes, 2010
- British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009British Journal of Dermatology, 2009
- Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based studyBritish Journal of Dermatology, 2007
- Current severe psoriasis and the Rule of TensBritish Journal of Dermatology, 2005
- A Catalog of Dermatology Utilities: A Measure of the Burden of Skin DiseasesJournal of Investigative Dermatology Symposium Proceedings, 2004
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990
- Utility approach to measuring health-related quality of lifeJournal of Chronic Diseases, 1987